S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
Is Graphite the New Lithium? (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
Stock market today: Global shares mixed as investors await debt ceiling vote, eye China economy
Is Graphite the New Lithium? (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Economic boost or big business hand-out? Nevada lawmakers consider A's stadium financing
OTCMKTS:ARGSQ

Argos Therapeutics (ARGSQ) Stock Forecast, Price & News

$0.05
0.00 (0.00%)
(As of 10/10/2019)
Compare
Today's Range
$0.05
$0.05
50-Day Range
$0.05
$0.05
52-Week Range
$0.02
$0.25
Volume
N/A
Average Volume
13,394 shs
Market Capitalization
$571,698.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARGSQ stock logo

About Argos Therapeutics (OTCMKTS:ARGSQ) Stock

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

Receive ARGSQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARGSQ Stock News Headlines

Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Outrage as Argos sells G-strings for children
Argos
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
Argos Therapeutics Inc (ARGSQ)
See More Headlines
Receive ARGSQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Argos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARGSQ Company Calendar

Last Earnings
8/09/2017
Today
5/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ARGSQ
Fax
N/A
Employees
21
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.90 million
Book Value
($1.63) per share

Miscellaneous

Free Float
N/A
Market Cap
$571,698.00
Optionable
Not Optionable
Beta
2.47

Key Executives

  • Dr. Charles A. Nicolette (Age 57)
    Consultant
  • Mr. Jeffrey D. Abbey (Age 57)
    Consultant & Director
  • Dr. Richard D. Katz (Age 55)
    Consultant
  • Ms. Lori R. Harrelson CPA (Age 50)
    CPA, VP of Fin.
  • Mr. William N. Wofford
    Sec.













ARGSQ Stock - Frequently Asked Questions

How have ARGSQ shares performed in 2023?

Argos Therapeutics' stock was trading at $0.0540 at the beginning of the year. Since then, ARGSQ stock has increased by 0.0% and is now trading at $0.0540.
View the best growth stocks for 2023 here
.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) announced its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million.

When did Argos Therapeutics' stock split?

Argos Therapeutics shares reverse split before market open on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the OTCMKTS under the ticker symbol "ARGSQ."

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Argos Therapeutics' stock price today?

One share of ARGSQ stock can currently be purchased for approximately $0.05.

How much money does Argos Therapeutics make?

Argos Therapeutics (OTCMKTS:ARGSQ) has a market capitalization of $571,698.00 and generates $1.90 million in revenue each year.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The official website for the company is www.argostherapeutics.com. The biopharmaceutical company can be reached via phone at 919-287-6300.

This page (OTCMKTS:ARGSQ) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -